Table of Contents
Introduction
New York, NY – January 7, 2025– Global Antipsychotic Drugs Market size was valued at USD 18.0 Billion in 2023 and is expected to grow to USD 29.5 Billion in 2032. Between 2024 and 2032, this market is estimated to register a CAGR of 5.8%. In 2022, North America led the market, achieving over 45% share with a revenue of US$ 7.65 Billion.
Antipsychotic medications, also known as neuroleptics, are widely used to manage symptoms associated with psychosis. These medications help reduce and control symptoms such as paranoia, auditory hallucinations, delusions, and hearing voices. They function by inhibiting the activity of dopamine and other neurotransmitters in the brain. The market currently offers both first-generation and second-generation antipsychotic drugs.
The rising prevalence of psychotic disorders is a key factor driving market demand. According to a World Health Organization report published in June 2022, one in eight people globally experienced mental health disorders in 2019. The COVID-19 pandemic further amplified the burden, leading to a 26% increase in anxiety disorders and a 28% rise in major depressive disorders within a year. This surge significantly boosted the demand for antipsychotic medications, propelling market growth.
Key Takeaways
- The global antipsychotic drugs market was valued at USD 17 billion in 2022.
- It is projected to reach USD 29.5 billion by 2032, growing at a CAGR of 5.8% between 2023 and 2032.
- Second-generation antipsychotics dominated the market by therapeutic class in 2022.
- Schizophrenia accounted for the largest market share in the disease analysis for 2022.
- Hospital pharmacies emerged as the leading distribution channel, holding the largest market share in 2022.
- North America led the market in 2022 with the highest revenue share of 45%.
- The Asia-Pacific (APAC) region is anticipated to witness the fastest growth rate (CAGR) among all regions.
Diseases Analysis of Antipsychotic Drugs Market
- Schizophrenia: Antipsychotics are central to the treatment of schizophrenia, addressing core symptoms such as hallucinations, delusions, and disorganized thinking. Long-term treatment often involves atypical antipsychotics due to their reduced risk of side effects compared to typical antipsychotics.
- Bipolar Disorder: In bipolar disorder, antipsychotics are used to manage acute manic episodes and can help prevent future episodes. They are sometimes used in conjunction with mood stabilizers or as monotherapy, particularly in severe cases.
- Unipolar Depression: Antipsychotics may be used as an adjunct treatment in unipolar depression, especially when symptoms are resistant to standard antidepressant therapies. They are often prescribed alongside antidepressants to enhance efficacy and address treatment-resistant aspects of depression.
- Dementia: Antipsychotics can be prescribed for managing aggression, psychosis, and agitation in dementia patients. However, their use is controversial due to potential severe side effects, including an increased risk of death, and should be used cautiously as a last resort when non-pharmacological interventions fail.
- Other Diseases: Antipsychotics are also used in the treatment of conditions such as severe anxiety, agitation, and psychotic symptoms associated with other mental health disorders. Their use is tailored to individual symptoms and conditions, emphasizing the importance of careful diagnostic and treatment planning.
Key Player Analysis
- AbbVie Inc. In August 2024: AbbVie completed its acquisition of Cerevel Therapeutics, enhancing its neuroscience portfolio with promising clinical-stage assets. This strategic move includes emraclidine, a potential next-generation antipsychotic currently in trials for schizophrenia. The acquisition is expected to contribute to AbbVie’s revenue growth into the next decade.
- Sumitomo Dainippon Pharma Co. Ltd. In September 2021: Sumitomo Dainippon Pharma and Otsuka Pharmaceutical entered into a worldwide collaboration for the development and commercialization of novel antipsychotic compounds. This partnership aims to advance four promising compounds addressing serious neuropsychiatric disorders, including ulotaront (SEP-363856), a potential treatment for schizophrenia.
- Alkermes Plc In June 2021: Alkermes announced the U.S. FDA approval of LYBALVI (olanzapine and samidorphan) for the treatment of adults with schizophrenia and bipolar I disorder. LYBALVI offers the established efficacy of olanzapine with reduced weight gain, addressing a significant side effect associated with antipsychotic treatment.
- AstraZeneca Plc As of January 2025: there have been no recent publicly announced acquisitions, mergers, or new product launches by AstraZeneca Plc specifically related to the antipsychotic drugs market.
- Dr. Reddy’s Laboratories Ltd. As of January 2025: there have been no recent publicly announced acquisitions, mergers, or new product launches by Dr. Reddy’s Laboratories Ltd. specifically related to the antipsychotic drugs market.
- Eli Lilly and Company As of January 2025: there have been no recent publicly announced acquisitions, mergers, or new product launches by Eli Lilly and Company specifically related to the antipsychotic drugs market.
Emerging Trends
- Development of Novel Mechanisms of Action: Recent approvals, such as the FDA’s September 2024 authorization of Cobenfy (xanomeline and trospium chloride), highlight a shift towards antipsychotics targeting non-dopaminergic pathways. Cobenfy is the first to act on cholinergic receptors, offering an alternative for schizophrenia treatment. This development reflects a broader trend of diversifying therapeutic targets to enhance efficacy and reduce side effects.
- Emphasis on Personalized Medicine: There’s a growing focus on tailoring antipsychotic treatments to individual patient profiles, considering genetic, metabolic, and lifestyle factors. This personalized approach aims to optimize therapeutic outcomes and minimize adverse effects, aligning with the broader movement towards precision medicine in healthcare.
- Integration of Digital Health Technologies: The incorporation of digital tools, such as mobile health applications and wearable devices, is enhancing patient monitoring and adherence to antipsychotic regimens. These technologies facilitate real-time tracking of symptoms and medication compliance, improving overall treatment management.
- Increased Scrutiny of Off-Label Antipsychotic Use: Regulatory bodies are intensifying evaluations of antipsychotic prescriptions, particularly concerning off-label uses. Studies indicate a decrease in antipsychotic use for conditions like dementia, accompanied by a rise in alternative treatments. This trend underscores the importance of evidence-based prescribing practices to ensure patient safety.
- Advancements in Long-Acting Injectable Formulations: The development of long-acting injectable (LAI) antipsychotics is gaining momentum, offering sustained drug release and improved adherence for patients with chronic psychotic disorders. LAIs reduce the need for daily dosing, addressing challenges related to medication compliance and enhancing long-term treatment outcomes.
Use Cases
- Schizophrenia Treatment: Antipsychotics are the cornerstone in managing schizophrenia, effectively reducing symptoms such as hallucinations, delusions, and thought disorders. Both first-generation (typical) and second-generation (atypical) antipsychotics are employed, with atypical agents often preferred due to a more favorable side effect profile. The National Institute of Mental Health emphasizes their role in improving patient outcomes and quality of life.
- Bipolar Disorder Management: In bipolar disorder, antipsychotics are used to treat acute manic or mixed episodes and, in some cases, bipolar depression. They help stabilize mood and prevent recurrence of mood episodes. The U.S. Food and Drug Administration has approved certain antipsychotics for this purpose, underscoring their efficacy in mood stabilization.
- Adjunctive Treatment in Major Depressive Disorder: For individuals with major depressive disorder who do not respond adequately to antidepressants alone, certain atypical antipsychotics can be added to enhance therapeutic effects. This adjunctive use aims to alleviate persistent depressive symptoms, as noted by the National Institute of Mental Health.
- Management of Psychosis in Dementia: Antipsychotics are sometimes prescribed to manage severe agitation, aggression, or psychosis in dementia patients when non-pharmacological interventions are ineffective. However, due to potential risks, including increased mortality, their use is approached with caution, as highlighted by the U.S. Food and Drug Administration.
- Treatment of Tourette Syndrome and Other Tic Disorders: Certain antipsychotics are effective in reducing the frequency and severity of tics in individuals with Tourette syndrome and other tic disorders. The National Institute of Mental Health acknowledges their role in improving patient functioning and quality of life.
Conclusion
The global antipsychotic drugs market is poised for significant growth, projected to expand from USD 17 billion in 2022 to USD 29.5 billion by 2032, at a CAGR of 5.8%. This growth is driven by the increasing prevalence of psychotic disorders, intensified by the COVID-19 pandemic. Second-generation antipsychotics, known for their reduced side effects, dominate the market. North America currently leads in revenue, while the Asia-Pacific region is expected to experience the fastest growth.
Key industry players are engaging in strategic acquisitions and partnerships to enhance their portfolios with innovative treatments, such as novel antipsychotic compounds and long-acting injectables. Additionally, the trend towards personalized medicine and the integration of digital health technologies indicate a forward-looking approach to improving patient outcomes in the antipsychotic drugs market.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
